In light of GILD raising $10 billion in a convertible bond offering, I did a little digging into who might be an attractive acquisition target, not only for them, but any major pharma. This is all speculation on my part. It’s almost impossible to guess which R&D mill will be acquired next, which is why I added in a small caveat of $250 million minimum in annual revenues into my screen.
This way, I am only producing real companies with real businesses. In the event my merger pipe dreams fail, at least I’ll still own a company that could survive on its own, without the help of capital markets to keep it afloat.
Surprisingly, the list of “real” companies with growth, in the biotech space, is rather exclusive.
Here is what I came up with. For Exodus members, the screens are here and here.
HZNP
DEPO
INSY
TECH
LCI
ACOR
ACET
EBS
SGEN
ISIS
INCY
BMRN
ENDP
GRFS
ILMN
MDVN
JAZZ
UTHR
I limited the scope of the screen to companies with market caps below $30 billion, for obvious reasons.
If you enjoy the content at iBankCoin, please follow us on Twitter
VVUS? too speculative ?
ARNA usually bounce back fast on period’ lows
Doesn’t reach min threshold of 250mill revenues.
My guess is BMRN
One could also ask, what is the next biotech to drop 80% in a day on an adverse FDA ruling or other catastrophe? I salute those who make these trades work; I have not been able to do so thus far.
Dr. Fly – I need this kind of info. Thank you.
I’m long GILD for the next 5-10 years, and also long SGEN. This is my biotech deal dream.
ICPT is clearly in the running too and bite sized
ISIS with its strong pipeline at a discount here….still too pricey?
My guess is that it’s anyone’s guess so not worth throwing money at.